89BIO INC. - COMMON STOCK

89bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 May 2023 16:05:00 By Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

02 May 2023 08:00:01 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock

24 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

22 Mar 2023 16:16:12 By Nasdaq GlobeNewswire

89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

22 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

10 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

04 Mar 2023 13:30:00 By Nasdaq GlobeNewswire

89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

89bio to Participate in the SVB Securities Global Biopharma Conference

08 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

89bio Provides Business Update and Outlook for 2023

04 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology

12 Dec 2022 18:30:00 By Nasdaq GlobeNewswire

89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

10 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022

05 Nov 2022 13:00:00 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

13 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 08:00:03 By Nasdaq GlobeNewswire

89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022

26 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH

18 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

11 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

05 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

29 Jun 2022 01:47:09 By Nasdaq GlobeNewswire